Patents Assigned to ZymoGenetics
  • Kunitz domain polypeptide zkun10
    Patent number: 6914135
    Abstract: Proteinase inhibitors comprising a Kunitz domain are disclosed. The Kunitz domain comprises a motif of amino acid residues as shown in SEQ ID NO:4, and the sequence of the Kunitz domain is shown in residues 57 through 107 of SEQ ID NO:2. The polypeptide also includes an N-terminal collagen domain in which a von Willebrand domain resides, and is shown in SEQ ID NO: 5. Also disclosed are methods for making the proteinase inhibitors, and expression vectors and cultured cells that are useful within the methods. The proteinase inhibitors may be used as components of cell culture media, in protein purification, and as inhibitors of protease degradation of plasma proteins.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: July 5, 2005
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Brian A. Fox
  • Methods for enhancing the expression of a protein of interest by recombinant host cells
    Patent number: 6908751
    Abstract: The increased use of nucleotide sequence data mining techniques has amplified the demand for efficient methods of producing recombinant proteins in eukaryotic cells. A strategy is provided for enhancing the synthesis of recombinant amino acid sequences by polymerizing expression cassettes in vitro before producing recombinant hosts.
    Type: Grant
    Filed: April 25, 2001
    Date of Patent: June 21, 2005
    Assignee: ZymoGenetics, Inc.
    Inventor: Si Lok
  • Murine interferon-?
    Patent number: 6902729
    Abstract: Interferons represent an important class of biopharmaceutical products, which have a proven track record in the treatment of a variety of medical conditions, including the treatment of certain autoimmune diseases, the treatment of particular cancers, and the enhancement of the immune response against infectious agents. The present invention provides a new form of murine interferon-?, which has applications in diagnosis and therapy.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: June 7, 2005
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Andrew L. Feldhaus, Zeren Gao
  • Human 2-19 protein homologue z219C
    Patent number: 6902911
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for z219c, a novel member of the human 2-19 protein family. The polypeptides, and polynucleotides encoding them, may be used for detecting various human disease states and chromosomal abnormalities. The present invention also includes antibodies to the z219c polypeptides.
    Type: Grant
    Filed: November 4, 1998
    Date of Patent: June 7, 2005
    Assignee: ZymoGenetics, Inc.
    Inventors: Darrell C. Conklin, Hal Blumberg, Theresa A. Deisher
  • Zsig33-like peptides
    Patent number: 6897286
    Abstract: The present invention relates to peptides related to the zsig33 peptide, including agonists, antagonists, and antibodies. Methods of modulating gastric contractility, nutrient uptake, growth hormones, the secretion of digestive enzymes and hormones, and/or secretion of enzymes and/or hormones in the pancreas are also included.
    Type: Grant
    Filed: May 10, 2001
    Date of Patent: May 24, 2005
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Paul O. Sheppard, Theresa A. Deisher, Paul D. Bishop
  • Human cytokine receptor
    Patent number: 6897292
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.
    Type: Grant
    Filed: December 1, 2000
    Date of Patent: May 24, 2005
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen
  • Method of treating fibrosis
    Patent number: 6893637
    Abstract: Materials and Methods for treating fibrosis in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf3 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Zvegf3 antagonists include anti-zvegf3 antibodies, mitogenically inactive receptor-binding zvegf3 variant polypeptides, and inhibitory polynucleotides. Within one embodiment of the fibrosis is liver fibrosis.
    Type: Grant
    Filed: October 23, 2000
    Date of Patent: May 17, 2005
    Assignee: ZymoGenetics, Inc.
    Inventor: Debra G. Gilbertson
  • Method for inhibiting the formation of seromas using factor XIII
    Patent number: 6890903
    Abstract: Use of factor XIII for inhibiting the formation of seromas by administering factor XIII. The factor XIII can be administered locally at the site of a wound or surgery or administered systemically. If the factor XIII is administered locally, it can be activated or non-activated and may be administered in conjunction with activated thrombin.
    Type: Grant
    Filed: October 9, 2002
    Date of Patent: May 10, 2005
    Assignee: Zymogenetics Inc.
    Inventors: Paul D. Bishop, Angelika Grossmann
  • Antibodies reactive to the c-terminal portion of growth factor homolog zvegf3
    Patent number: 6887982
    Abstract: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residues 235-345 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: May 3, 2005
    Assignee: ZymoGenetics, Inc.
    Inventors: Zeren Gao, Charles E. Hart, Christopher S. Piddington, Paul O. Sheppard, Kimberly E. Shoemaker
  • Transglutaminase ztg2
    Patent number: 6887695
    Abstract: Transglutaminase polypeptides, polynucleotides encoding them, methods of making them, and methods of using them are disclosed. The polypeptides comprise residues 1-X of SEQ ID NO:2, wherein X is an integer from 462 to 704, inclusive. The compositions and methods of the invention may be used for a variety of purposes in industry, research, and medicine.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: May 3, 2005
    Assignee: ZymoGenetics, Inc.
    Inventor: Brian A. Fox
  • Zace1: a human metalloenzyme
    Patent number: 6878810
    Abstract: Angiotensin-converting enzyme is a zinc metallopeptidase that plays roles in blood pressure regulation and fertility. The catalytic activities of angiotensin converting enzymes include the production of the potent vasopressor angiotensin II from angiotensin I, and the inactivation of the vasodilatory peptide bradykinin. Zace1 is a new form of human zinc metallopeptidase, which includes one zinc-dependent catalytic domain containing the motif “HEXXH” and one downstream “EX(I/V)X(D/S)” motif.
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: April 12, 2005
    Assignee: ZymoGenetics, Inc.
    Inventor: Paul O. Sheppard
  • Mouse cytokine receptor
    Patent number: 6875845
    Abstract: Cytokines and their receptors have proven usefulness in both basic research, animal models, and as therapeutics. The present invention provides a new cytokine receptor designated as “mouse Zcytor16,” which can bind and antagonize the IL-TIF cytokine.
    Type: Grant
    Filed: March 4, 2002
    Date of Patent: April 5, 2005
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen
  • Method for treating cytokine mediated hepatic injury
    Patent number: 6875742
    Abstract: A method of modulating cytokine mediated hepatic injury by administering compound-D SEQ ID NO:1 to a mammal. A concentration of the compound in the range of about 0.5 mg/kg to about 20 mg/kg in a physiologically acceptable formulation blocks a cytokine cascade. A therapeutic method of modulating cytokine mediated acute inflammatory, trauma induced and toxin induced hepatic injury, particularly via tumor necrosis factor modulation, is thus disclosed.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: April 5, 2005
    Assignees: ZymoGenetics, Inc., University of Kentucky Research Foundation
    Inventors: Peter R. Oeltgen, Paul D. Bishop, Craig J. McClain, Shirish Barve
  • Methods for promoting growth of bone, ligament, and cartilage using zvegf4
    Patent number: 6866991
    Abstract: Methods for promoting growth of bone, ligament, or cartilage in a mammal are disclosed. The methods comprise administering to said mammal a composition comprising a pharmacologically effective amount of zvegf4 in combination with a pharmaceutically acceptable delivery vehicle. Also disclosed are methods for promoting proliferation or differentiation of osteoblasts, osteoclasts, chondrocytes, or bone marrow stem cells comprising culturing the cells in an effective amount of zvegf4.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: March 15, 2005
    Assignee: ZymoGenetics, Inc.
    Inventors: Debra G. Gilbertson, Charles E. Hart
  • Motilin Homologs
    Patent number: 6838438
    Abstract: The present invention is directed to polynucleotides, polypeptides and peptide fragments thereof, and uses thereof for a novel cDNA sequence which has homology to motilin. Tissue distribution of the mRNA for the novel polypeptide is specific to the stomach, small intestine and pancreas. The present invention further includes agonists, antagonists, antibodies, host cells expressing the cDNA encoding the novel motilin homologs and methods for increasing gastric motility using the novel molecules.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: January 4, 2005
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Theresa A. Deisher, Paul D. Bishop, Stephen R. Jaspers, Virender M. Labroo
  • Antibodies to mammalian adhesion protease peptides
    Publication number: 20040259163
    Abstract: The present invention relates to polynucleotide and polypeptide molecules, and variants thereof, for MAPP, a novel member of the Disintegrin Proteases. The polypeptides, and polynucleotides encoding them, are cell-cell interaction modulating and may be used for delivery and therapeutics. The present invention also includes antibodies to the MAPP polypeptides.
    Type: Application
    Filed: May 25, 2004
    Publication date: December 23, 2004
    Applicant: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Nand Baindur, Paul D. Bishop
  • Novel human kunitz-type inhibitors and methods relating thereto
    Publication number: 20040253686
    Abstract: The present invention provides isolated DNA molecules comprising a DNA segment encoding novel human Kunitz-type inhibitors. Also provided are DNA constructs comprising a first DNA segment encoding a novel human Kunitz-type inhibitor wherein said first DNA segment is operably linked to additional DNA segments required for the expression for the first DNA segment, as well as host cells containing such DNA constructs and methods for producing proteins from the host cells.
    Type: Application
    Filed: October 7, 2003
    Publication date: December 16, 2004
    Applicants: ZymoGenetics, Inc., The University of New Mexico
    Inventors: Cindy A. Sprecher, Walt Kisiel, Donald C. Foster
  • MOTILIN HOMOLOGS
    Publication number: 20040254345
    Abstract: The present invention is directed to polynucleotides, polypeptides and peptide fragments thereof, and uses thereof for a novel cDNA sequence which has homology to motilin. Tissue distribution of the mRNA for the novel polypeptide is specific to the stomach, small intestine and pancreas. The present invention further includes agonists, antagonists, antibodies, host cells expressing the cDNA encoding the novel motilin homologs and methods for increasing gastric motility using the novel molecules.
    Type: Application
    Filed: February 28, 2001
    Publication date: December 16, 2004
    Applicant: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Theresa A. Deisher, Paul D. Bishop, Stephen R. Jaspers, Virender M. Labroo
  • Antibodies that bind human Zven1
    Patent number: 6828425
    Abstract: The present invention provides two members of a new family of human proteins, designated as “Zven.” The Zven1 gene, which resides in human chromosome 3p21.1-3p14.3, is expressed in testicular tissue and peripheral blood lymphocytes.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: December 7, 2004
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Paul D. Bishop
  • Secreted salivary zsig63 polypeptide
    Patent number: 6828419
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zsig63, a novel secreted salivary protein. The polypeptides, and polynucleotides encoding them, may exhibit anti-microbial activity and may be used in the study or treatment of microbial infections. The polynucleotides encoding zsig63, are located on chromosome 4, and can be used to identify a region of the genome associated with human disease states. The present invention also includes antibodies to the zsig63 polypeptides.
    Type: Grant
    Filed: August 3, 2001
    Date of Patent: December 7, 2004
    Assignee: ZymoGenetics, Inc.
    Inventors: David A. Adler, Paul O. Sheppard